NCT01157845View on ClinicalTrials.gov

Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis

PHASE3CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Cirrhosis
Interventions
DEVICE

BreathID (Methacetin breath test)

13C-labeled methacetin (75 mg) is given to the patient by mouth in a small volume of water, and expired 13C-labeled carbon dioxide is measured from a nasal cannula.

Trial Locations (4)

23298

Virginia Commonwealth University Medical Center, Richmond

29425

Medical University of South Carolina, Charleston

48202

Henry Ford Health System, Detroit

91120

Hadassah Medical Center, Jerusalem

Sponsors

Collaborators (1)

Meridian Bioscience, Inc.
All Listed Sponsors
collaborator

Meridian Bioscience, Inc.

INDUSTRY

lead

Virginia Commonwealth University

OTHER

NCT01157845 - Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis | Biotech Hunter | Biotech Hunter